Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-08-01 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 133.1 KB | ||
| 2023-07-27 22:30 |
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
|
English | 158.5 KB | ||
| 2023-07-27 22:30 |
Cellectis présentera ses résultats financiers du deuxième trimestre 2023 le 3 a…
|
French | 148.6 KB | ||
| 2023-07-12 22:30 |
Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
|
English | 145.1 KB | ||
| 2023-07-12 22:30 |
Cellectis nomme le docteur Cécile Chartier, Ph.D. à son conseil d’administration
|
French | 148.2 KB | ||
| 2023-07-05 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 81.3 KB | ||
| 2023-07-05 22:30 |
Monthly information on share capital and company voting rights
|
English | 81.9 KB | ||
| 2023-06-28 22:30 |
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held o…
|
English | 119.2 KB | ||
| 2023-06-28 22:30 |
Résultats de l’Assemblée Générale Mixte des Actionnaires de Cellectis du 27 jui…
|
French | 126.1 KB | ||
| 2023-06-13 22:30 |
Monthly information on share capital and company voting rights
|
English | 81.8 KB | ||
| 2023-06-13 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 81.3 KB | ||
| 2023-06-09 22:30 |
Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the E…
|
English | 96.4 KB | ||
| 2023-06-09 22:30 |
Cellectis présente des données cliniques et translationnelles actualisées de so…
|
French | 73.4 KB | ||
| 2023-06-05 22:30 |
Cellectis a dévoilé des données précliniques à l’occasion d’une présentation or…
|
French | 118.6 KB | ||
| 2023-06-05 22:30 |
Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Pre…
|
English | 106.4 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
